Cataldo, Maria Letizia
Cataldo, Maria Letizia
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance
2019 Nardone, A.; Weir, H.; Delpuech, O.; Brown, H.; De Angelis, C.; Cataldo, M. L.; Fu, X.; Shea, M. J.; Mitchell, T.; Veeraraghavan, J.; Nagi, C.; Pilling, M.; Rimawi, M. F.; Trivedi, M.; Hilsenbeck, S. G.; Chamness, G. C.; Jeselsohn, R.; Osborne, C. K.; Schiff, R.
FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer
2019 Fu, X.; Pereira, R.; De Angelis, C.; Veeraraghavan, J.; Nanda, S.; Qin, L.; Cataldo, M. L.; Sethunath, V.; Mehravaran, S.; Gutierrez, C.; Chamness, G. C.; Feng, Q.; O'Malley, B. W.; Selenica, P.; Weigelt, B.; Reis-Filho, J. S.; Cohen, O.; Wagle, N.; Nardone, A.; Jeselsohn, R.; Brown, M.; Rimawi, M. F.; Osborne, C. K.; Schiff, R.
Activation of the IFN signaling pathway is associated with resistance to CDK4/6 inhibitors and immune checkpoint activation in ER-positive breast cancer
2021 De Angelis, C.; Fu, X.; Cataldo, M. L.; Nardone, A.; Pereira, R.; Veeraraghavan, J.; Nanda, S.; Qin, L.; Sethunath, V.; Wang, T.; Hilsenbeck, S. G.; Benelli, M.; Migliaccio, I.; Guarducci, C.; Malorni, L.; Litchfield, L. M.; Liu, J.; Donaldson, J.; Selenica, P.; Brown, D. N.; Weigelt, B.; Reis-Filho, J. S.; Park, B. H.; Hurvitz, S. A.; Slamon, D. J.; Rimawi, M. F.; Jansen, V. M.; Jeselsohn, R.; Osborne, C. K.; Schiff, R.
Evaluation of the predictive role of tumor immune infiltrate in HER2-positive breast cancer patients treated with neoadjuvant anti-HER2 therapy without chemotherapy
2020 De Angelis, Carmine; Nagi, Chandandeep; Hoyt, Cliff C; Liu, Linying; Roman, Kristin; Wang, Chichung; Zheng, Yi; Veeraraghavan, Jamunarani; Sethunath, Vidyalakshmi; Nuciforo, Paolo; Wang, Tao; Tsimelzon, Anna; Mao, Sufeng; Hilsenbeck, Susan G; Trivedi, Meghana V; Cataldo, Maria Letizia; Pavlick, Anne; Wolff, Antonio C; Weigelt, Britta; Reis-Filho, Jorge S; Prat, Aleix; Gutierrez, Carolina; Osborne, Charles Kent; Rimawi, Mothaffar F; Schiff, Rachel
NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer
2022 Bhat, R.; Thangavel, H.; Abdulkareem, N. M.; Vasaikar, S.; De Angelis, C.; Bae, L.; Cataldo, M. L.; Nanda, S.; Fu, X.; Zhang, B.; Schiff, R.; Trivedi, M. V.
The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer
2023 Cataldo, Maria Letizia; De Placido, Pietro; Esposito, Daniela; Formisano, Luigi; Arpino, Grazia; Giuliano, Mario; Bianco, Roberto; De Angelis, Carmine; Veneziani, Bianca Maria
| Titolo | Tipologia | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|---|
| The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance | 1.1 Articolo in rivista | 2019 | Nardone, A.; Weir, H.; Delpuech, O.; Brown, H.; De Angelis, C.; Cataldo, M. L.; Fu, X.; Shea, M. J.; Mitchell, T.; Veeraraghavan, J.; Nagi, C.; Pilling, M.; Rimawi, M. F.; Trivedi, M.; Hilsenbeck, S. G.; Chamness, G. C.; Jeselsohn, R.; Osborne, C. K.; Schiff, R. | |
| FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer | 1.1 Articolo in rivista | 2019 | Fu, X.; Pereira, R.; De Angelis, C.; Veeraraghavan, J.; Nanda, S.; Qin, L.; Cataldo, M. L.; Sethunath, V.; Mehravaran, S.; Gutierrez, C.; Chamness, G. C.; Feng, Q.; O'Malley, B. W.; Selenica, P.; Weigelt, B.; Reis-Filho, J. S.; Cohen, O.; Wagle, N.; Nardone, A.; Jeselsohn, R.; Brown, M.; Rimawi, M. F.; Osborne, C. K.; Schiff, R. | |
| Activation of the IFN signaling pathway is associated with resistance to CDK4/6 inhibitors and immune checkpoint activation in ER-positive breast cancer | 1.1 Articolo in rivista | 2021 | De Angelis, C.; Fu, X.; Cataldo, M. L.; Nardone, A.; Pereira, R.; Veeraraghavan, J.; Nanda, S.; Qin, L.; Sethunath, V.; Wang, T.; Hilsenbeck, S. G.; Benelli, M.; Migliaccio, I.; Guarducci, C.; Malorni, L.; Litchfield, L. M.; Liu, J.; Donaldson, J.; Selenica, P.; Brown, D. N.; Weigelt, B.; Reis-Filho, J. S.; Park, B. H.; Hurvitz, S. A.; Slamon, D. J.; Rimawi, M. F.; Jansen, V. M.; Jeselsohn, R.; Osborne, C. K.; Schiff, R. | |
| Evaluation of the predictive role of tumor immune infiltrate in HER2-positive breast cancer patients treated with neoadjuvant anti-HER2 therapy without chemotherapy | 1.1 Articolo in rivista | 2020 | De Angelis, Carmine; Nagi, Chandandeep; Hoyt, Cliff C; Liu, Linying; Roman, Kristin; Wang, Chichung; Zheng, Yi; Veeraraghavan, Jamunarani; Sethunath, Vidyalakshmi; Nuciforo, Paolo; Wang, Tao; Tsimelzon, Anna; Mao, Sufeng; Hilsenbeck, Susan G; Trivedi, Meghana V; Cataldo, Maria Letizia; Pavlick, Anne; Wolff, Antonio C; Weigelt, Britta; Reis-Filho, Jorge S; Prat, Aleix; Gutierrez, Carolina; Osborne, Charles Kent; Rimawi, Mothaffar F; Schiff, Rachel | |
| NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer | 1.1 Articolo in rivista | 2022 | Bhat, R.; Thangavel, H.; Abdulkareem, N. M.; Vasaikar, S.; De Angelis, C.; Bae, L.; Cataldo, M. L.; Nanda, S.; Fu, X.; Zhang, B.; Schiff, R.; Trivedi, M. V. | |
| The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer | 1.1 Articolo in rivista | 2023 | Cataldo, Maria Letizia; De Placido, Pietro; Esposito, Daniela; Formisano, Luigi; Arpino, Grazia; Giuliano, Mario; Bianco, Roberto; De Angelis, Carmine; Veneziani, Bianca Maria |